ERBB2 and breast carcinoma: A study using G129R (PRLR antagonist) and trastuzumab (monoclonal antibody targeting HER2) as a combination therapy to inhibit HER2+ breast cancer cells and a nude mouse xenograft model showed inhibition of cell proliferation (102).